Similar articles for PMID: 29208326

Year	Number of Results
2001	1
2006	2
2008	1
2009	2
2013	1
2014	6
2015	16
2016	23
2017	13
2018	12
2019	22
2020	6
2021	11
2022	9
2023	13
2024	0

1

A review on the antagonist Ebola: A prophylactic approach.

Khan FN, Qazi S, Tanveer K, Raza K. Khan FN, et al. Biomed Pharmacother. 2017 Dec;96:1513-1526. doi: 10.1016/j.biopha.2017.11.103. Epub 2017 Dec 6. Biomed Pharmacother. 2017. PMID: 29208326 Free PMC article. Review.

2

Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus.

Dhama K, Karthik K, Khandia R, Chakraborty S, Munjal A, Latheef SK, Kumar D, Ramakrishnan MA, Malik YS, Singh R, Malik SVS, Singh RK, Chaicumpa W. Dhama K, et al. Front Immunol. 2018 Aug 10;9:1803. doi: 10.3389/fimmu.2018.01803. eCollection 2018. Front Immunol. 2018. PMID: 30147687 Free PMC article. Review.

3

Development of therapeutics for treatment of Ebola virus infection.

Li H, Ying T, Yu F, Lu L, Jiang S. Li H, et al. Microbes Infect. 2015 Feb;17(2):109-17. doi: 10.1016/j.micinf.2014.11.012. Epub 2014 Dec 11. Microbes Infect. 2015. PMID: 25498866 Free article. Review.

4

Insights into Ebola Virus VP35 and VP24 Interferon Inhibitory Functions and their Initial Exploitation as Drug Targets.

Fanunza E, Frau A, Corona A, Tramontano E. Fanunza E, et al. Infect Disord Drug Targets. 2019;19(4):362-374. doi: 10.2174/1871526519666181123145540. Infect Disord Drug Targets. 2019. PMID: 30468131 Review.

5

The Drug Targets and Antiviral Molecules for Treatment of Ebola Virus Infection.

Wu W, Liu S. Wu W, et al. Curr Top Med Chem. 2017;17(3):361-370. doi: 10.2174/1568026616666160829161318. Curr Top Med Chem. 2017. PMID: 27572081 Review.

6

Comprehensive Review on Ebola (EBOV) Virus: Future Prospects.

Khan S, Muhammad, Rauf A, Khan A, Rizwan M, Patel S, Khan H, Mahasneh AM, Mubarak MS. Khan S, et al. Infect Disord Drug Targets. 2018;18(2):96-104. doi: 10.2174/1871526517666170817100828. Infect Disord Drug Targets. 2018. PMID: 28820067 Review.

7

Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection.

Tshiani Mbaya O, Mukumbayi P, Mulangu S. Tshiani Mbaya O, et al. Front Immunol. 2021 Aug 30;12:721328. doi: 10.3389/fimmu.2021.721328. eCollection 2021. Front Immunol. 2021. PMID: 34526994 Free PMC article. Review.

8

Perspectives towards antiviral drug discovery against Ebola virus.

Mirza MU, Vanmeert M, Ali A, Iman K, Froeyen M, Idrees M. Mirza MU, et al. J Med Virol. 2019 Dec;91(12):2029-2048. doi: 10.1002/jmv.25357. Epub 2019 Sep 30. J Med Virol. 2019. PMID: 30431654 Free PMC article. Review.

9

Treatment of ebola virus disease.

Kilgore PE, Grabenstein JD, Salim AM, Rybak M. Kilgore PE, et al. Pharmacotherapy. 2015 Jan;35(1):43-53. doi: 10.1002/phar.1545. Pharmacotherapy. 2015. PMID: 25630412 Review.

10

Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid Protection.

Menicucci AR, Jankeel A, Feldmann H, Marzi A, Messaoudi I. Menicucci AR, et al. mBio. 2019 May 28;10(3):e00597-19. doi: 10.1128/mBio.00597-19. mBio. 2019. PMID: 31138743 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

123 results

Results by year